EFFECTS OF ATORVASTATIN IN TYPE III HYPERLIPIDEMIA--OPEN EXTENSION STUDY

阿托伐他汀对Ⅲ型高脂血症的作用--开放扩展研究

• 批准号: 6116952
• 负责人: D ROGER ILLINGWORTH
• 金额: $ 3.13万
• 依托单位: OREGON HEALTH & SCIENCE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6116952
• 关键词: antihypercholesterolemic agent; blood lipoprotein metabolism; clinical research; clinical trials; drug administration rate /duration; drug screening /evaluation; familial hyperlipoproteinemia type III; human subject; human therapy evaluation; lovastatin; metabolism disorder chemotherapy; steroid metabolism

This study will compare the hypolipidemic effects and influence on lipoprotein and cholesterol metabolism gemfibrozil, simvastatin and atorvastatin in patients with type III hyperlipidemia. After a 4 week dietary baseline, patients will be treated in a random sequence with gemfibrozil (1,200 mg/day), simvastatin (40 mg/day) or atorvastatin (10 mg/day or 80 mg/day) each for 8 weeks; efficacy, metabolic effects and safety will be evaluated on each regimen.

本研究将比较两种方法的降血脂效果及对血脂的影响， 脂蛋白和胆固醇代谢吉非贝齐、辛伐他汀和 阿托伐他汀治疗III型高脂血症。 4周后 饮食基线，患者将接受随机序列治疗， 吉非贝齐（1，200 mg/天）、辛伐他汀（40 mg/天）或阿托伐他汀（10 mg/天或80 mg/天），持续8周;疗效、代谢作用和 将对每种方案的安全性进行评价。